ArticleInternational journal of surgery (London, England)2026
Ferroptosis in renal cell carcinoma: integrative multi-omics insights and therapeutic perspectives.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated spatial and single‑cell transcriptomics maps disulfidptosis in renal cell carcinoma and reveals PDLIM1 as a prognostic biomarker and potential therapeutic target.Translational oncology · 2026Article
- Article
- Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy.Frontiers in oncology · 2026Review
- Unraveling the Crosstalk Between Ferroptosis and Cuproptosis for Rational Nanomedicine Design in Cancer.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) exhibits marked heterogeneity in its molecular landscape and clinical behavior. Ferroptosis, an iron-dependent and lipid peroxidation-driven form of cell death, has emerged as a biologically relevant process in RCC pathogenesis. This review summarizes recent advances in the multi-omics dissection of ferroptosis in RCC, including findings from genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics. Key molecular regulators such as VHL, SLC7A11, GPX4, and ACSL4 are highlighted for their roles in ferroptosis sensitivity or resistance. In parallel, insights from single-cell and spatial omics offer new perspectives on cell-type specificity and microenvironmental context. We also discuss the implications of ferroptosis in therapeutic modulation, including potential integration with immune checkpoint inhibitors and metabolic interventions. This review aims to provide a coherent overview of ferroptosis in RCC and inform future mechanistic studies and translational strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.